Gérald Luscan
Publications by Year
Research Areas
Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Health Systems, Economic Evaluations, Quality of Life, Healthcare Decision-Making and Restraints, Biological Research and Disease Studies
Most-Cited Works
- → Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials(2016)293 cited
- → Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies(2016)38 cited
- → European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials(2018)29 cited
- → Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19(2024)27 cited
- → Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings(2020)23 cited
- → Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial(2024)9 cited
- → A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma(2023)2 cited
- → Additional file 2: of Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies(2016)
- → Additional file 1: of Bapineuzumab for mild to moderate Alzheimerâ s disease in two global, randomized, phase 3 trials(2016)